Literature DB >> 6762305

Immunocytochemical localization of HLA-DR in human islets of Langerhans.

R Alejandro, F L Shienvold, S V Hajek, U Ryan, J Miller, D H Mintz.   

Abstract

Previous reports of allogeneic transplantation studies in rodents have postulated that the primary carriers of Ia antigen in islets of Langerhans are passenger leukocytes. We sought to demonstrate directly the localization of the analogous human antigen, HLA-DR, in islet-enriched fractions (IEFs), utilizing a nonpolymorphic monoclonal anti-DR (alpha DR) antibody. The presence of DR in the IEFs was first demonstrated by radioimmunobinding assay. Light microscopic immunocytochemistry, in frozen sections of intact (unfixed) human pancreas, revealed a staining pattern suggestive of a vascular distribution of DR in islets. Ultrastructural localization of DR was then carried out by indirect immunoperoxidase labeling in the presence of NaN3 (to prevent internalization of bound alpha DR). The major site of DR expression in the islet was the endothelial cell surface. Endocrine cells were entirely devoid of alpha DR binding. Nonislet endothelium was also heavily labeled, but acinar and ductal cells were completely negative. Leukocytes bound alpha DR but were relatively rare in the IEFs. Human islets, therefore, clearly express HLA-DR, but predominantly on insular endothelial cells. Isolation of pure endocrine cell populations, specifically free of endothelium, would appear to be a rational approach to reducing immunogenicity in allogeneic transplantation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6762305     DOI: 10.2337/diab.31.4.s17

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Primary and immortalised human pancreatic islet endothelial cells: phenotypic and immunological characterisation.

Authors:  E Favaro; A Bottelli; B Lozanoska-Ochser; E Ferioli; G C Huang; N Klein; A Chiaravalli; P Cavallo Perin; G Camussi; M Peakman; P G Conaldi; M M Zanone
Journal:  Diabetologia       Date:  2005-11-15       Impact factor: 10.122

2.  Immunologic factors in pathogenesis and treatment of human and animal diabetes.

Authors:  A Naji; W K Silvers; S T Bartlett; J Francfort; C F Barker
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

Review 3.  Immunopathology of the human pancreas in type-I diabetes.

Authors:  Sarah J Richardson; Abby Willcox; Adrian J Bone; Noel G Morgan; Alan K Foulis
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

4.  [In vitro and in vivo studies of isolation, transplantation and function of Langerhans islets in the swine].

Authors:  U J Hesse; J Danis; J Weyer; G Meyer; S Saad
Journal:  Langenbecks Arch Chir       Date:  1990

5.  Comparative immunocytochemical study of MHC class II expression in human donor pancreas and isolated islets.

Authors:  W Lu; D G Pipeleers; G Klöppel; L Bouwens
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

6.  A ganglioside antigen on the rat pancreatic B cell surface identified by monoclonal antibody R2D6.

Authors:  R Alejandro; F L Shienvold; S A Hajek; M Pierce; R Paul; D H Mintz
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

7.  Insulitis as a consequence of immune dysregulation: further evidence.

Authors:  K Flohr; U Kiesel; G Freytag; H Kolb
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

8.  Islet Dysfunction in a Novel Transgenic Model of T Cell Insulitis.

Authors:  Emily Esakov; Neha Nandedkar-Kulkarni; Ali G Al-Dieri; Hannah Hafner; Brigid Gregg; Marcia F McInerney
Journal:  Biomolecules       Date:  2021-04-09

9.  Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus.

Authors:  A K Foulis; M A Farquharson; R Hardman
Journal:  Diabetologia       Date:  1987-05       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.